ORPHA:679
Malignant atrophic papulosis
Also known as: Cutaneo-muco-intestinal syndrome · MAP · Papulosis atrophicans maligna
Publications
951
Trials
2
Interventional, condition-specific
Researchers
882
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Malignant atrophic papulosis (MAP) is a rare, chronic, thrombo-obliterative vasculopathy characterized by papular skin lesions with central porcelain-white atrophy and a surrounding teleangiectatic rim. Systemic lesions may affect the gastrointestinal tract and the central nervous system (CNS) and are potentially lethal.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0011208
- MeSH:D054853
- OMIM:602248
- UMLS:C0221011
- NCIT:C84835
Additional Mondo synonyms (8)
Degos Disease · Degos disease · Kohlmeier-Degos disease · Kohlmeier-Degos-Delort-Tricort syndrome · Köhlmeier-Degos disease · Köhlmeier-Degos-Delort-Tricort syndrome · malignant atrophic papulosis · papulosis atrophican maligna
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
951 matched papers (433 in last 10 years) Source
- Phenotype characterisedPresent
41 HPO annotations (e.g. Fatigue; Myocardial infarction; Respiratory failure) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
2 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
41
Associated phenotypes · MONDO:0011208
- Fatigue
- Myocardial infarction
- Respiratory failure
- Abnormality of the lower urinary tract
- Amaurosis fugax
Showing 5 of 41 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
2
Drugs / clinical candidates · MONDO_0011208
- BARICITINIB·phase 2
- RUXOLITINIB·phase 1 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
951
951 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
951 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
433 in the last 10 years · low confidence
Phrase hits: 951 · MeSH hits: 0
Who's working on it?
882
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Magro CM12 papers · 2026
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Papers in Europe PMC - 02
- 03Zouboulis CC8 papers · 2023
Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, Germany.
Papers in Europe PMC - 04Shapiro LS6 papers · 2021
Rheumatology, Albany Medical College, Ballston Spa, NY, USA.
Papers in Europe PMC - 05Kumar S5 papers · 2026
Institute of Human Genetics, University of Bonn, Medical Faculty & University Hospital Bonn, Bonn, Germany.
Papers in Europe PMC - 06Theodoridis A5 papers · 2022
Departments of Dermatology, Venerology, Allergology and Immunology, Dessau Medical Center, Auenweg 38, Dessau, 06847, Germany.
Papers in Europe PMC - 07Betz RC4 papers · 2025
Institute of Human Genetics, University of Bonn, Medical Faculty & University Hospital Bonn, Bonn, Germany. Electronic address: regina.betz@uni-bonn.de.
Papers in Europe PMC - 08Frank J4 papers · 2025
Department of Dermatology, Venereology and Allergology, University Medical Center Goettingen, Goettingen, Germany.
Papers in Europe PMC - 09Levy R4 papers · 2022
Division of Dermatology, Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada.
Papers in Europe PMC - 10Lu JD4 papers · 2022
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
2
interventional trials for this specific condition
2 interventional trials matched this specific condition name; 1 currently recruiting in our sample.
Data as of 11 September 2026
2 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 84.5th percentile).
low confidence · 84.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
2 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06923072·RECRUITING·Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement
Not reviewed·Conditions: Kohlmeier-Degos Disease · Malignant Atrophic Papulosis · Degos Disease · Papulosis, Malignant Atrophic·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Malignant atrophic papulosis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Malignant atrophic papulosis" OR "Cutaneo-muco-intestinal syndrome" OR "Papulosis atrophicans maligna" OR "Degos Disease" OR "Kohlmeier-Degos disease" OR "Kohlmeier-Degos-Delort-Tricort syndrome" OR "Köhlmeier-Degos disease" OR "Köhlmeier-Degos-Delort-Tricort syndrome" OR "papulosis atrophican maligna"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Malignant atrophic papulosis" OR "Cutaneo-muco-intestinal syndrome" OR "Papulosis atrophicans maligna" OR "Degos Disease" OR "Kohlmeier-Degos disease" OR "Kohlmeier-Degos-Delort-Tricort syndrome" OR "Köhlmeier-Degos disease" OR "Köhlmeier-Degos-Delort-Tricort syndrome" OR "papulosis atrophican maligna"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 2 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: MAP
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- "Degos Disease" also appears on ORPHA:656071
- "Köhlmeier-Degos disease" also appears on ORPHA:656071
- Publication count (951) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-26T14:54:40.824Z
